The Imbruvica Reckoning
2 filers across 1 sector are flagging lower demand. First surfaced in 2025Q2; tracked through 2026Q1. Almost entirely a demand story (100%). Recent filings describe "AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026." Still gaining momentum.
J&J and AbbVie are both experiencing sharp revenue declines for Imbruvica (ibrutinib) driven by competitive market pressure and Medicare Part D redesign impact, with particular weakness in U.S. demand and pricing.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from explaining past-period declines to describing an ongoing present-state demand collapse, suggesting the headwind is structural rather than transient.
REPRESENTATIVE SIGNAL FROM FILINGS
“AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026”
Global Imbruvica revenues declined 25% in the first quarter of 2026.
“IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Medicare Part D redesign.”
IMBRUVICA sales declined due to competitive pressures and Medicare Part D redesign impact.
DRIVERS